Jiangsu Hengrui Receives NMPA Approval for SHR-7631 ADC Clinical Study in Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Potential first-in-class
AbbVie Acquires Landos Biopharma to Boost Autoimmune Disease Pipeline
AbbVie (NYSE: ABBV) has announced its acquisition of Landos Biopharma (NASDAQ: LABP), a biopharmaceutical company...
FDA Grants Full Approval to AbbVie’s Elahere for Advanced Ovarian Cancer Treatment
This week, the U.S. Food and Drug Administration (FDA) granted full approval to AbbVie’s (NYSE:...
Novo Nordisk Acquires Cardior for €1.025 Billion to Strengthen Cardiovascular Portfolio
Denmark-based Novo Nordisk (CPH: NOVO-B) has announced a significant agreement to acquire Germany’s Cardior, a...
Jiangsu Hengrui Receives NMPA Approval for Phase Ib/II Study of HRS2398 in Advanced Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
MSD Partners with IDEAYA Biosciences to Develop Combination Therapy for Endometrial Cancer
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with IDEAYA Biosciences (NASDAQ:...
Shanghai Fosun Pharma Gets NMPA Green Light for Universal NK Cell Therapy GCK-01 Clinical Study
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
AbbVie Partners with OSE Immunotherapeutics to Develop First-in-Class Immunotherapy OSE-230
AbbVie (NYSE: ABBV) has entered into a strategic partnership with France-based OSE Immunotherapeutics (EPA: OSE)...
Bayer Advances BAY3018250 into Phase II Trial Following Successful Phase I Completion
Germany’s Bayer (ETR: BAYN) has launched a double-blind, placebo-controlled mid-stage trial for its potential first-in-class...
Immune-Onc Therapeutics Partners with Roche for Phase Ib/II Study of IO-108 in Liver Cancer
Immune-Onc Therapeutics Inc., based in the U.S., is entering into a collaboration with Roche (SWX:...
Phanes Therapeutics’ PT886 Receives CDE Approval for Clinical Trials in Advanced Solid Tumors
Sino-US biotechnology company Phanes Therapeutics Inc. has announced that it has received clinical trial approval...
Johnson & Johnson’s Talquetamab and Daiichi Sankyo’s Enhertu Eye Priority Review in China
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J, NYSE:...
Phanes Therapeutics’ First-in-Class BsAb PT217 Accepted for Review by China’s CDE
Sino-US biotechnology company Phanes Therapeutics Inc. has announced that the Investigational New Drug (IND) filing...
AstraZeneca Wins FDA Nod for Airsupra in Asthma Treatment
AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, announced this week that it has...
J&J’s Balversa Receives Full FDA Approval for Urothelial Carcinoma Treatment
The US Food and Drug Administration (FDA) has converted the 2019 accelerated approval for Johnson...
Lee’s Pharmaceutical to Develop Windtree’s Cardiovascular Drugs in Greater China
Lee’s Pharmaceutical Ltd (HKG: 0950) has entered into a licensing agreement with US-based Windtree Therapeutics...
Chipscreen NewWay Biosciences Initiates Phase I Trial for PD-1/CD40 Bispecific Antibody Candidate NWY001
China-based Chengdu Chipscreen NewWay Biosciences Co., Ltd has announced that the first patient has been...
Johnson & Johnson to Acquire Ambrx Biopharma in a Deal Valued at USD 2 Billion
Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare conglomerate, has announced its intention to...
Astellas’ Zolbetuximab Faces FDA Rejection Due to Manufacturing Facility Deficiencies
The US Food and Drug Administration (FDA) has issued a rejection for a filing submitted...
Merck In-Licenses Inspirna’s Ompenaclid for Advanced Colorectal Cancer, Eyes Market Potential
Germany-based Merck (NYSE: MRK) has in-licensed the potential first-in-class candidate ompenaclid from U.S. firm Inspirna,...